A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

Trial Profile

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs RSIFN-co (Primary)
  • Indications Colorectal cancer; Lung cancer; Malignant melanoma; Neuroendocrine carcinoma; Prostate cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms EffTox
  • Sponsors Sichuan Huiyang Life Science and Technology Corporation
  • Most Recent Events

    • 29 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
    • 29 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 25 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top